{"id":58752,"date":"2026-03-04T13:55:13","date_gmt":"2026-03-04T05:55:13","guid":{"rendered":"https:\/\/flcube.com\/?p=58752"},"modified":"2026-03-04T13:55:13","modified_gmt":"2026-03-04T05:55:13","slug":"bio-theras-stelara-biosimilar-usymro-wins-uk-approval-expands-european-market-access-via-gedeon-richter","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58752","title":{"rendered":"Bio-Thera&#8217;s Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter"},"content":{"rendered":"\n<p><strong>Bio-Thera Solutions Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA:\u202f688177<\/a>)<\/strong> announced that the <strong>UK&#8217;s Medicines and Healthcare products Regulatory Agency (MHRA)<\/strong> has approved <strong>Usymro<\/strong>, a <strong>biosimilar version of Johnson &amp; Johnson&#8217;s Stelara (ustekinumab)<\/strong>. The approval covers <strong>adult patients<\/strong> with <strong>moderate\u2011to\u2011severe plaque psoriasis (PsO)<\/strong>, <strong>active psoriatic arthritis (PsA)<\/strong>, and <strong>moderately\u2011to\u2011severely active Crohn&#8217;s disease (CD)<\/strong>\u2014marking <strong>Bio-Thera&#8217;s UK market entry<\/strong> following <strong>US and EU approvals in 2024<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Bio-Thera Solutions Ltd (SHA:\u202f688177)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Usymro (ustekinumab biosimilar)<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Stelara (J&amp;J) \u2013 IL\u201112\/23 inhibitor<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>UK MHRA<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>March\u202f2026<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>PsO, PsA, CD (adults)<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>US (May\u202f2024), EU (Aug\u202f2024)<\/td><\/tr><tr><td><strong>China Status<\/strong><\/td><td>NMPA filing under review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-partnership-gedeon-richter\">Commercial Partnership \u2013 Gedeon Richter<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner<\/strong><\/td><td>Gedeon Richter<\/td><\/tr><tr><td><strong>Agreement Date<\/strong><\/td><td>October\u202f2024<\/td><\/tr><tr><td><strong>Bio-Thera Responsibilities<\/strong><\/td><td>R&amp;D, manufacturing, commercial supply<\/td><\/tr><tr><td><strong>Gedeon Richter Territory<\/strong><\/td><td>EU, UK, Switzerland, Australia, select European countries<\/td><\/tr><tr><td><strong>Gedeon Richter Role<\/strong><\/td><td>Commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Biosimilar Expansion:<\/strong> <strong>US + EU + UK approvals<\/strong> establish <strong>Bio-Thera as a tier\u2011one global biosimilar developer<\/strong>, capable of <strong>regulatory navigation<\/strong> across <strong>major pharmaceutical markets<\/strong>\u2014a significant achievement for <strong>Chinese biopharma<\/strong>.<\/li>\n\n\n\n<li><strong>Stelara Market Opportunity:<\/strong> Stelara generated <strong>~\u202f$10\u202fbillion<\/strong> globally in 2024; patent expiry creates <strong>$3\u20114\u202fbillion biosimilar opportunity<\/strong>; Usymro&#8217;s <strong>early mover advantage<\/strong> in UK\/EU positions for <strong>market share capture<\/strong>.<\/li>\n\n\n\n<li><strong>Gedeon Richter Synergy:<\/strong> The <strong>established European commercial partnership<\/strong> leverages <strong>Richter&#8217;s dermatology and gastroenterology sales infrastructure<\/strong>, avoiding <strong>proprietary build\u2011out costs<\/strong> and <strong>accelerating revenue generation<\/strong>.<\/li>\n\n\n\n<li><strong>China Market Pending:<\/strong> <strong>NMPA review<\/strong> underway; domestic approval would enable <strong>China launch<\/strong> and <strong>potential cost advantage<\/strong> in the <strong>world&#8217;s second\u2011largest pharmaceutical market<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>UK Biosimilar Market<\/strong><\/td><td>~\u202f\u00a32\u202fbillion annually; MHRA post\u2011Brexit regulatory independence enables streamlined approvals; strong payer preference for biosimilars<\/td><\/tr><tr><td><strong>Stelara Biosimilar Competition<\/strong><\/td><td>Amgen, Alvotech, and others launching 2024\u20112025; first\u2011to\u2011market advantage critical for formulary positioning<\/td><\/tr><tr><td><strong>IL\u201112\/23 Class Dynamics<\/strong><\/td><td>Stelara established standard for psoriasis\/Crohn&#8217;s; biosimilars expected to capture 40\u201150% market share within 3 years post\u2011launch<\/td><\/tr><tr><td><strong>Bio-Thera Pipeline Validation<\/strong><\/td><td>Usymro success supports <strong>batoclimab (anti\u2011FcRn)<\/strong>, <strong>tocilizumab biosimilar<\/strong>, and <strong>innovative ADC programs<\/strong>; demonstrates <strong>end\u2011to\u2011end biologics capabilities<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding UK commercial launch timelines, EU market penetration, and NMPA approval outcomes for Usymro. Actual results may differ due to risks including competitive Stelara biosimilar launches, pricing pressure in European tenders, and manufacturing capacity constraints.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions Ltd (SHA:\u202f688177) announced that the UK&#8217;s Medicines and Healthcare products Regulatory Agency (MHRA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[289,43,149,15,1055],"class_list":["post-58752","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bio-thera-solutions","tag-biosimilars","tag-johnson-johnson","tag-product-approvals","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera&#039;s Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions Ltd (SHA:\u202f688177) announced that the UK&#039;s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Usymro, a biosimilar version of Johnson &amp; Johnson&#039;s Stelara (ustekinumab). The approval covers adult patients with moderate\u2011to\u2011severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderately\u2011to\u2011severely active Crohn&#039;s disease (CD)\u2014marking Bio-Thera&#039;s UK market entry following US and EU approvals in 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58752\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera&#039;s Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions Ltd (SHA:\u202f688177) announced that the UK&#039;s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Usymro, a biosimilar version of Johnson &amp; Johnson&#039;s Stelara (ustekinumab). The approval covers adult patients with moderate\u2011to\u2011severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderately\u2011to\u2011severely active Crohn&#039;s disease (CD)\u2014marking Bio-Thera&#039;s UK market entry following US and EU approvals in 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58752\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T05:55:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58752#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58752\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera&#8217;s Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter\",\"datePublished\":\"2026-03-04T05:55:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58752\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bio-Thera Solutions\",\"Biosimilars\",\"Johnson &amp; Johnson\",\"Product approvals\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58752#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58752\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58752\",\"name\":\"Bio-Thera's Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-04T05:55:13+00:00\",\"description\":\"Bio-Thera Solutions Ltd (SHA:\u202f688177) announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Usymro, a biosimilar version of Johnson & Johnson's Stelara (ustekinumab). The approval covers adult patients with moderate\u2011to\u2011severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderately\u2011to\u2011severely active Crohn's disease (CD)\u2014marking Bio-Thera's UK market entry following US and EU approvals in 2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58752#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58752\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58752#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera&#8217;s Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera's Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions Ltd (SHA:\u202f688177) announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Usymro, a biosimilar version of Johnson & Johnson's Stelara (ustekinumab). The approval covers adult patients with moderate\u2011to\u2011severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderately\u2011to\u2011severely active Crohn's disease (CD)\u2014marking Bio-Thera's UK market entry following US and EU approvals in 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58752","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera's Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter","og_description":"Bio-Thera Solutions Ltd (SHA:\u202f688177) announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Usymro, a biosimilar version of Johnson & Johnson's Stelara (ustekinumab). The approval covers adult patients with moderate\u2011to\u2011severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderately\u2011to\u2011severely active Crohn's disease (CD)\u2014marking Bio-Thera's UK market entry following US and EU approvals in 2024.","og_url":"https:\/\/flcube.com\/?p=58752","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T05:55:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58752#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58752"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera&#8217;s Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter","datePublished":"2026-03-04T05:55:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58752"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bio-Thera Solutions","Biosimilars","Johnson &amp; Johnson","Product approvals","SHA: 688177"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58752#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58752","url":"https:\/\/flcube.com\/?p=58752","name":"Bio-Thera's Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-04T05:55:13+00:00","description":"Bio-Thera Solutions Ltd (SHA:\u202f688177) announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Usymro, a biosimilar version of Johnson & Johnson's Stelara (ustekinumab). The approval covers adult patients with moderate\u2011to\u2011severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderately\u2011to\u2011severely active Crohn's disease (CD)\u2014marking Bio-Thera's UK market entry following US and EU approvals in 2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58752#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58752"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58752#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera&#8217;s Stelara Biosimilar Usymro Wins UK Approval \u2013 Expands European Market Access via Gedeon Richter"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58752"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58752\/revisions"}],"predecessor-version":[{"id":58753,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58752\/revisions\/58753"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}